If oral Brilacidin proves to be successful for Ulcerative Colitis and/or Crohn's disease I would expect a trial for IBS, irritable bowel syndrome. IBS is a larger market than IBD.
While IBS is rarely a serious or disabiling condition it is a common malady without consistently effective treatments.
I
Glta Farrell
(8)
(2)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links